Why Seguro Popular Ended Seguro Popular was created in 2004 to provide healthcare coverage to Mexico’s uninsured population – those without access to IMSS or ISSSTE systems. It was a semi-decentralized model where the federal government provided funding, but states executed the delivery of services. Initially, it expanded access to millions, offering packages for basic…
The US administration’s push to restructure pharmaceutical supply chains through tariffs is gaining traction, and Mexico is now a key target. With existing 25% tariffs on Chinese pharmaceuticals and escalating trade pressure on Europe and India, including Mexico in this policy shift marks a major turning point. Why Mexico Matters in the Supply Chain Mexico…
Prescription Access without Delay In the US, getting a prescription often means seeing a doctor, waiting on insurance approval, and picking it up at a pharmacy that may or may not have it in stock. In Mexico, the process is significantly more direct. Licensed physicians are available for walk-in consults at many pharmacies. They write…
Mexico has become a popular destination for retirees, expatriates, and medical tourists seeking high-quality healthcare at lower costs than in the US or Canada. But navigating health insurance in Mexico can be complex, especially for foreigners unfamiliar with the system. Here’s a detailed look at the most common questions regarding health coverage in Mexico. Does…
Most medications require controlled conditions to remain effective, but the typical bathroom medicine cabinet is one of the worst possible storage locations. Fluctuations in temperature and humidity are frequent and extreme, especially after showers. Research published in the Journal of Pharmaceutical Sciences found that bathroom humidity can exceed 90% multiple times per day, even in…
Biaxin (clarithromycin) emerged in the early 1990s as a revolutionary antibiotic specifically tailored to tackle respiratory infections. Earlier antibiotics, like erythromycin or penicillin-based drugs, frequently struggled against stubborn respiratory pathogens, particularly atypical bacteria such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. Studies indicate that Biaxin reduces average symptom duration by about 35% compared to…